ClinicalTrials.gg
Not yet recruitingNCT05564169Updated Oct 3, 2025

Masitinib in Patients With Mild Alzheimer's Disease

A Phase 3 interventional study of Placebo and Masitinib (4.5) in Alzheimer Disease, sponsored by AB Science. Not yet recruiting at 9 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 278 studies in Alzheimer Disease with a site in Spain — 53 open to participants now, 79 under way, 24 of them phase 3. Alzheimer Disease · Spain.

Planned enrollment
63rd of 239
600 · median 259
Started
2026
with 17 others
Phase 3
79 of 278
12 open now
Primary completion
2028-12
later than 61 of 78 live
Registered
201st of 278
by date

Among the 278 studies in Alzheimer Disease with a site in Spain, this one is the 63rd largest by planned enrollment of the 239 interventional ones that give a count, is one of 18 that started in 2026, is one of 79 in phase 3, reaches primary completion later than 61 of the 78 other live ones, and was the 201st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

53 of the 278 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 278 studies in Alzheimer Disease with a site in Spain, or all of them as a file.
02

Study summary

Masitinib is an orally administered tyrosine kinase inhibitor that targets activated cells of the neuroimmune system (mast cells and microglia). Study AB21004 will evaluate masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.

Read the detailed description

Masitinib is an oral tyrosine kinase inhibitor that has demonstrated neuroprotective action in neurodegenerative diseases via inhibition of mast cell and microglia/macrophage activity, and which is capable of accumulating within the central nervous system (CNS) at a therapeutically relevant concentration. There is a growing body of evidence implicating mast cells and microglia (types of innate immune cells that are present in the CNS), with the pathophysiology of Alzheimer's disease.

Masitinib has been shown to restore normal spatial learning performance and promote recovery of synaptic markers in a mouse model of Alzheimer's disease, with its synapto-protective action being directly linked to mast cell inhibition. The potential benefit of masitinib in the treatment of patients with mild to moderate Alzheimer's disease has been previously demonstrated in a phase 2 study (AB04024; NCT00976118) and a positive phase 2B/3 study (AB09004; NCT01872598) that showed masitinib (4.5 mg/kg/day) was associated with a statistically significant slowing of cognitive deterioration.

The objective of study AB21004 is to confirm treatment effect with masitinib as an adjunct to cholinesterase inhibitor and/or memantine in patients with mild-to-moderate Alzheimer's disease.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimer's Disease
  • Mast Cells
  • Microglia
  • Tyrosine kinase inhibitor
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria include:

  1. Patient with clinical diagnosis of Alzheimer's disease based on criteria defined by IWG (International Working Group on Alzheimer's disease) at screening visit.
  2. Patients with ADCS-ADL score at screening visit and baseline visit \< 73
  3. Patient with ≥ 21 and ≤ 25 at screening visit and baseline visit.
  4. Patient with Alzheimer's Disease biomarker profile at screening visit:

    • A positive amyloid PET scan
    • Alternatively, positive a-beta AND p-tau results OR an abnormal p-tau/a-beta ratio in CSF analysis. Before randomization, the results will be verified centrally.
  5. If patients are treated with cholinesterase inhibitors (donepezil, rivastigmine or galantamine), and/or memantine. They should have been at stable dose for a minimum of 6 months at baseline visit, with no changes foreseen in therapy throughout the trial.
  6. If receiving a supplement for cognition (eg, gingko biloba, omega-3 polyunsaturated fatty acid, vitamin E, curcumin, souvenaid) patients must have been taking it at stable dose for at least 4 months prior to screening visit.
  7. Patients with a caregiver who, at screening and baseline visits, agrees to accompany the participant to all trial visits, supervise compliance with procedures, provide detailed information, has sufficient contact (≥1 hour/day for ≥3 days/week or as deemed sufficient by the Investigator), can read, understand, and speak the designated language, and is cognitively capable of fulfilling trial requirements.

Main exclusion criteria include:

Related to disease

  1. Patients with any other cause of dementia shown by MRI findings and neurological examination
  2. Systemic conditions known to cause dementia, e.g., hypothyroidism, untreated vitamin B12 or folic acid deficiency, niacin deficiency, neurosyphilis, infection at screening visit.
  3. Patients with substance-induced dementia, Alzheimer's disease with delirium, severe delusions (e.g., NPI delusion score ≥ 4), psychosis or antipsychotic use, or a history of significant psychiatric disorders at the screening visit.
  4. Patients with a significant unexplained improvement or decline in overall status on ADAS-Cog and ADCS-ADL at screening and baseline compared to previous assessments, and those whose scores are not in line with their medical history.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Masitinib (4.5) & SOC

    Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment. Dose up-titration is subjected to a safety control. Masitinib will be administered as an add-on to cholinesterase inhibitor and/or memantine standard of care (SOC).

    Drug: Masitinib (4.5) · Drug: Standard of care

  • Placebo comparator
    Placebo & SOC

    Participants receive a matched dose placebo, given orally twice daily. Placebo will be administered as an add-on to cholinesterase inhibitor and/or memantine standard of care (SOC).

    Drug: Placebo · Drug: Standard of care

Interventions

  • DrugPlacebo

    treatment per os

    Also known as: Placebo Oral Tablet

  • Masitinib (titration to 4.5 mg/kg/day)

    Also known as: AB1010

  • DrugStandard of care

    Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in iADRS score at week 24

    The iADRS is a linear combination of its two components: the ADAS-Cog11 and the ADCS-iADL. The iADRS is calculated as follows: iADRS = ADCS-iADL + (70 - ADAS-Cog11). Lower scores on the iADRS indicate greater impairment; iADRS scores range from 0 to 129.

    Time frame: 24 weeks

Secondary outcomes

  1. Absolute change from baseline in Mini-Mental State Examination (MMSE) at week 24

    Mini-Mental State Examination (MMSE) (scores from 0 to 30, with lower scores indicating poorer cognitive performance)

    Time frame: 24 weeks

  2. Absolute change from baseline in ADAS-Cog11 score at week 24

    The global score, which is the sum of the 11 items, ranges from 0 to 70, with higher scores indicating greater cognitive impairment.

    Time frame: 24 weeks

  3. Absolute change from baseline in ADCS-ADL score

    Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL) (scores from 0 to 78, with lower scores indicating worse function)

    Time frame: 48 weeks

  4. Clinical Responder rate

    Clinical response defined as decrease from baseline at week 24 in ADAS-cog of ≥4, without deterioration in ADCS-ADL (ADCS-ADL change ≥ 0 between baseline and timepoint) or worsening in the CIBIC-plus scale (response CIBIC in 1-3\] or no change \[CIBIC in 4\]).

    Time frame: 24 weeks

  5. CIBIC-plus

    Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus), a seven-point categorical rating scale ranging from 1 (marked improved) to 7 (markedly worse) compared with baseline.

    Time frame: 24 weeks

  6. Absolute change from baseline in CDR

    Clinical Dementia Rating (CDR), scores from 0 to 18, with higher scores indicating worse dementia

    Time frame: 24 weeks

  7. Time to severe dementia (MMSE<10)

    Mini-Mental State Examination (MMSE) (scores from 0 to 30, with lower scores indicating poorer cognitive performance)

    Time frame: 24 weeks

  8. Absolute change from baseline in ADAS-Cog11 score at week 48

    The global score, which is the sum of the 11 items, ranges from 0 to 70, with higher scores indicating greater cognitive impairment.

    Time frame: 48 weeks

  9. Absolute change from baseline in ADCS-ADL score at week 24

    Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL) (scores from 0 to 78, with lower scores indicating worse function)

    Time frame: 24 weeks

  10. Absolute change from baseline in Neuropsychiatric Inventory (NPI) at week 24

    Total NPI-12 score ranges from 0 to 144 (higher = more severe symptoms)

    Time frame: 24 weeks

07

Study locations

9 sites
  • Institut de la mémoire et Maladie d'Alzheimer, Hôpitaux Universitaires Pitié-Salpêtrière
    Paris, France
  • Hospital Universitario Nuestra Señora del Perpetuo Socorro de Albacete (Hospital Universitario Nuestra Señora del Perpétuo Socorro)
    Albacete, Spain
  • Ace Alzheimer Center Barcelona (Fundació ACE)
    Barcelona, Spain
  • Hospital Policlínico de Gipuzkoa
    Donostia / San Sebastian, Spain
  • Virgen de las Nieves University Hospital (Hospital Universitario Virgen de las Nieves)
    Granada, Spain
  • La Paz University Hospital (Hospital Universitario La Paz)
    Madrid, Spain
  • Hospital Clinico Universitario Virgen de la Arrixaca
    Murcia, Spain
  • Hospital Universitario de Navarra
    Pamplona, Spain
  • Complejo Asistencial de Zamora. Hospital Provincial de Zamora
    Zamora, Spain
08

References and documents

Publications

  • Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011 Apr 19;3(2):16. doi: 10.1186/alzrt75. PubMed 21504563 ↗
  • Dubois B, Lopez-Arrieta J, Lipschitz S, Doskas T, Spiru L, Moroz S, Venger O, Vermersch P, Moussy A, Mansfield CD, Hermine O, Tsolaki M; AB09004 Study Group Investigators. Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. Alzheimers Res Ther. 2023 Feb 28;15(1):39. doi: 10.1186/s13195-023-01169-x. PubMed 36849969 ↗
  • Li T, Martin E, Abada YS, Boucher C, Ces A, Youssef I, Fenaux G, Forand Y, Legrand A, Nachiket N, Dhenain M, Hermine O, Dubreuil P, Delarasse C, Delatour B. Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease. J Alzheimers Dis. 2020;76(4):1339-1345. doi: 10.3233/JAD-200466. PubMed 32623401 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Dec 2028, 30 months later.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 30 months is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2022
First posted
Oct 3, 2022
StartEst.
Jun 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05564169
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Oct 3, 2022
Start date
Jun 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Oct 3, 2025

Study contacts

Clinical Study Coordinator
Contact
clinical@ab-science.com
+33(0)147200014
Bruno Dubois, MD, PhD
principal investigator · Hôpital Universitaire Pitié-Salpêtrière, Paris, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion